CS314490A2 - Stable, cosmetically acceptable topic gel-like preparation - Google Patents

Stable, cosmetically acceptable topic gel-like preparation Download PDF

Info

Publication number: CS314490A2
Authority: CS; Czechoslovakia
Prior art keywords: stable; topical; pharmaceutical; gel composition; acid
Prior art date: 1989-06-27

Application number

CS903144A

Other languages

Czech (cs)

English (en)

Inventor

Lawrence Ritter

Original Assignee

American Cyanamid Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-27

Filing date

1990-06-25

Publication date

1991-11-12

1990-06-25 Application filed by American Cyanamid Co filed Critical American Cyanamid Co

1991-11-12 Publication of CS314490A2 publication Critical patent/CS314490A2/cs

Links

238000002360 preparation method Methods 0.000 title claims description 13
239000000203 mixture Substances 0.000 claims description 78
-1 polyethylene Polymers 0.000 claims description 24
230000000699 topical effect Effects 0.000 claims description 23
239000002904 solvent Substances 0.000 claims description 20
229940072172 tetracycline antibiotic Drugs 0.000 claims description 20
239000004098 Tetracycline Substances 0.000 claims description 16
229960002180 tetracycline Drugs 0.000 claims description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
239000004698 Polyethylene Substances 0.000 claims description 14
229920000573 polyethylene Polymers 0.000 claims description 14
229960004023 minocycline Drugs 0.000 claims description 12
150000001875 compounds Chemical class 0.000 claims description 10
239000006184 cosolvent Substances 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 10
239000003349 gelling agent Substances 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 8
229920001577 copolymer Polymers 0.000 claims description 8
XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 7
229940086555 cyclomethicone Drugs 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 6
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 5
229920001519 homopolymer Polymers 0.000 claims description 5
231100000252 nontoxic Toxicity 0.000 claims description 5
230000003000 nontoxic effect Effects 0.000 claims description 5
229920001296 polysiloxane Polymers 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 4
MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 claims description 4
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 4
150000004677 hydrates Chemical class 0.000 claims description 4
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 4
DJNTZVRUYMHBTD-UHFFFAOYSA-N Octyl octanoate Chemical compound CCCCCCCCOC(=O)CCCCCCC DJNTZVRUYMHBTD-UHFFFAOYSA-N 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000000499 gel Substances 0.000 claims description 3
239000004014 plasticizer Substances 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
DHWLRNPWPABRBG-UHFFFAOYSA-N tridecyl 2,2-dimethylpropanoate Chemical compound CCCCCCCCCCCCCOC(=O)C(C)(C)C DHWLRNPWPABRBG-UHFFFAOYSA-N 0.000 claims description 3
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 claims description 2
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
229920002126 Acrylic acid copolymer Polymers 0.000 claims description 2
YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 2
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 2
150000001298 alcohols Chemical class 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
125000004663 dialkyl amino group Chemical group 0.000 claims description 2
229940031578 diisopropyl adipate Drugs 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
229940089456 isopropyl stearate Drugs 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
229960001679 octinoxate Drugs 0.000 claims description 2
229960003921 octisalate Drugs 0.000 claims description 2
ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 claims description 2
JYQFMBYXIWYNBD-UHFFFAOYSA-N tridecyl octanoate Chemical compound CCCCCCCCCCCCCOC(=O)CCCCCCC JYQFMBYXIWYNBD-UHFFFAOYSA-N 0.000 claims description 2
239000008252 pharmaceutical gel Substances 0.000 claims 7
KGKQNDQDVZQTAG-UHFFFAOYSA-N 8-methylnonyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCOC(=O)C(C)(C)C KGKQNDQDVZQTAG-UHFFFAOYSA-N 0.000 claims 1
FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 claims 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
VVAGLQUBKXRJGG-UHFFFAOYSA-N OP(O)(=O)OP(=O)(O)O.C(C(C)O)O Chemical compound OP(O)(=O)OP(=O)(O)O.C(C(C)O)O VVAGLQUBKXRJGG-UHFFFAOYSA-N 0.000 claims 1
229920006397 acrylic thermoplastic Polymers 0.000 claims 1
239000000654 additive Substances 0.000 claims 1
230000000996 additive effect Effects 0.000 claims 1
125000003282 alkyl amino group Chemical group 0.000 claims 1
150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 claims 1
229940074928 isopropyl myristate Drugs 0.000 claims 1
229940075495 isopropyl palmitate Drugs 0.000 claims 1
229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
229920000642 polymer Polymers 0.000 claims 1
MBHCWRKFAXKMRT-UHFFFAOYSA-N propanoic acid;1-tetradecoxytetradecane Chemical compound CCC(O)=O.CCCCCCCCCCCCCCOCCCCCCCCCCCCCC MBHCWRKFAXKMRT-UHFFFAOYSA-N 0.000 claims 1
125000001424 substituent group Chemical group 0.000 claims 1
ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 claims 1
238000009472 formulation Methods 0.000 description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
208000035475 disorder Diseases 0.000 description 13
235000019364 tetracycline Nutrition 0.000 description 13
229930101283 tetracycline Natural products 0.000 description 13
FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 10
WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 9
229960002421 minocycline hydrochloride Drugs 0.000 description 9
239000003242 anti bacterial agent Substances 0.000 description 8
239000003814 drug Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 8
150000003522 tetracyclines Chemical class 0.000 description 8
229940088710 antibiotic agent Drugs 0.000 description 7
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 7
239000000047 product Substances 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
230000003115 biocidal effect Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000000354 decomposition reaction Methods 0.000 description 5
235000011962 puddings Nutrition 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
239000002537 cosmetic Substances 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
210000000115 thoracic cavity Anatomy 0.000 description 4
229940042129 topical gel Drugs 0.000 description 4
UCOXGFBGSLDEPZ-ADMKQJKVSA-N (4s,4as,5ar,12ar)-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-7-(methylamino)-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)C(C(O)=CC=C4NC)=C4C[C@H]3C[C@H]21 UCOXGFBGSLDEPZ-ADMKQJKVSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000006071 cream Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000012049 topical pharmaceutical composition Substances 0.000 description 3
NWXMGUDVXFXRIG-PMXORCKASA-N (4r,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-PMXORCKASA-N 0.000 description 2
FZKWRPSUNUOXKJ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrate Chemical compound O.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O FZKWRPSUNUOXKJ-CVHRZJFOSA-N 0.000 description 2
AZXUDNJDZHNFIH-REXXEDAASA-N (4s,4as,5ar,12ar)-2-carbamoyl-4-(dimethylazaniumyl)-10,11,12a-trihydroxy-9-(methylamino)-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracen-1-olate Chemical compound CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)C4=C(O)C(NC)=CC=C4C[C@H]3C[C@H]21 AZXUDNJDZHNFIH-REXXEDAASA-N 0.000 description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
241000186427 Cutibacterium acnes Species 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
239000004100 Oxytetracycline Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
229960003722 doxycycline Drugs 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
210000003780 hair follicle Anatomy 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229940127249 oral antibiotic Drugs 0.000 description 2
229960000625 oxytetracycline Drugs 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000003586 protic polar solvent Substances 0.000 description 2
229920002050 silicone resin Polymers 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
239000004099 Chlortetracycline Substances 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010014950 Eosinophilia Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010016936 Folliculitis Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010058015 Infected cyst Diseases 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010024648 Livedo reticularis Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000233679 Peronosporaceae Species 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
206010046914 Vaginal infection Diseases 0.000 description 1
201000008100 Vaginitis Diseases 0.000 description 1
KRPAPDCTWMTYHU-UHFFFAOYSA-N [Li]C#N Chemical compound [Li]C#N KRPAPDCTWMTYHU-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
206010000496 acne Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000002519 antifouling agent Substances 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
229960004475 chlortetracycline Drugs 0.000 description 1
CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
230000002995 comedolytic effect Effects 0.000 description 1
230000007797 corrosion Effects 0.000 description 1
238000005260 corrosion Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
230000007423 decrease Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229960002398 demeclocycline Drugs 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
208000010227 enterocolitis Diseases 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000001339 epidermal cell Anatomy 0.000 description 1
238000006345 epimerization reaction Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
230000005294 ferromagnetic effect Effects 0.000 description 1
210000001061 forehead Anatomy 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000003350 kerosene Substances 0.000 description 1
238000002372 labelling Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
201000003102 mental depression Diseases 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
229940042016 methacycline Drugs 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
230000008693 nausea Effects 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
235000019366 oxytetracycline Nutrition 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920005638 polyethylene monopolymer Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
MILWSGRFEGYSGM-UHFFFAOYSA-N propane-1,2-diol;propane-1,2,3-triol Chemical compound CC(O)CO.OCC(O)CO MILWSGRFEGYSGM-UHFFFAOYSA-N 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
210000001732 sebaceous gland Anatomy 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
241001148471 unidentified anaerobic bacterium Species 0.000 description 1
239000012808 vapor phase Substances 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
- A61K8/8111—Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Dermatology (AREA)
Birds (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

CS903144A 1989-06-27 1990-06-25 Stable, cosmetically acceptable topic gel-like preparation CS314490A2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/371,948 US5122519A (en)	1989-06-27	1989-06-27	Stable, cosmetically acceptable topical gel formulation and method of treatment for acne

Publications (1)

Publication Number	Publication Date
CS314490A2 true CS314490A2 (en)	1991-11-12

Family

ID=23466067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS903144A CS314490A2 (en)	1989-06-27	1990-06-25	Stable, cosmetically acceptable topic gel-like preparation

Country Status (16)

Country	Link
US (1)	US5122519A (fr)
EP (1)	EP0410099A1 (fr)
JP (1)	JPH0348615A (fr)
KR (1)	KR910000162A (fr)
CN (1)	CN1048322A (fr)
AU (1)	AU5789990A (fr)
CA (1)	CA2019724A1 (fr)
CS (1)	CS314490A2 (fr)
FI (1)	FI903216A7 (fr)
HU (1)	HU204435B (fr)
IE (1)	IE902307A1 (fr)
IL (1)	IL94490A0 (fr)
NO (1)	NO902828L (fr)
PL (1)	PL285813A1 (fr)
PT (1)	PT94485A (fr)
ZA (1)	ZA904971B (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5494903A (en)	1991-10-04	1996-02-27	American Cyanamid Company	7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
USRE40183E1 (en)	1991-10-04	2008-03-25	Wyeth Holdings Corporation	7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
FR2715294B1 (fr)	1994-01-26	1996-03-22	Oreal	Composition cosmétique ou dermatologique anhydre contenant l'association d'une huile de silicone et d'une cire d'un homo- ou copolymère d'éthylène .
US5648066A (en) *	1995-10-03	1997-07-15	Estee Lauder Companies	Solid silicone compositions and methods for their preparation and use
US6998138B2 (en) *	1996-02-19	2006-02-14	Acrux Dds Pty. Ltd.	Topical delivery of anti-alopecia agents
US6923983B2 (en)	1996-02-19	2005-08-02	Acrux Dds Pty Ltd	Transdermal delivery of hormones
US7094422B2 (en) *	1996-02-19	2006-08-22	Acrux Dds Pty Ltd.	Topical delivery of antifungal agents
US6929801B2 (en) *	1996-02-19	2005-08-16	Acrux Dds Pty Ltd	Transdermal delivery of antiparkinson agents
AUPN814496A0 (en) *	1996-02-19	1996-03-14	Monash University	Dermal penetration enhancer
US6916486B2 (en) *	1996-02-19	2005-07-12	Acrux Dds Pty Ltd	Transdermal delivery of analgesics
US6916487B2 (en) *	1996-02-19	2005-07-12	Acrux Dds Pty Ltd	Transdermal delivery of antiemetics
US6187695B1 (en) *	1998-12-08	2001-02-13	Kimberly-Clark Worldwide, Inc.	Cool feeling tissue product and method
CA2254237A1 (fr) *	1997-12-30	1999-06-30	Kimberly-Clark Worldwide, Inc.	Mouchoir a effet rafraichissant et methode connexe
CA2318580A1 (fr) *	1998-01-23	1999-07-29	Mark L. Nelson	Composes pharmaceutiquement actifs et procedes d'utilisation correspondants
ATE336238T1 (de) *	1998-11-18	2006-09-15	Collagenex Pharm Inc	Neue 4-dedimethylaminotetracyclinderivate
US6946453B2 (en)	1998-11-18	2005-09-20	Collagenex Pharmaceuticals, Inc.	4-dedimethylaminotracycline derivatives
US6506740B1 (en) *	1998-11-18	2003-01-14	Robert A. Ashley	4-dedimethylaminotetracycline derivatives
FR2806624B1 (fr) *	2000-03-22	2002-10-31	Rhodia Chimie Sa	Systeme huile silicone/co-solvant concentre en matiere(s) active(s) cosmetique(s) liposoluble(s), emulsion et formulation cosmetiques correspondantes
JP4653282B2 (ja) *	2000-05-23	2011-03-16	昭和薬品化工株式会社	ミノサイクリン含有組成物
US8512718B2 (en)	2000-07-03	2013-08-20	Foamix Ltd.	Pharmaceutical composition for topical application
US6387383B1 (en) *	2000-08-03	2002-05-14	Dow Pharmaceutical Sciences	Topical low-viscosity gel composition
US6503894B1 (en)	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
US7211267B2 (en)	2001-04-05	2007-05-01	Collagenex Pharmaceuticals, Inc.	Methods of treating acne
AU2002303250B2 (en) *	2001-04-05	2006-05-25	Collagenex Pharmaceuticals, Inc.	Methods of treating acne
US6375938B1 (en)	2001-04-26	2002-04-23	The Gillette Company	Antiperspirant and deodorant compositions containing a low molecular weight polyethylene gellant
RU2300380C2 (ru) *	2001-10-05	2007-06-10	Тетрадженекс Фармасьютикалс, Инк.	Производные тетрациклина и способы их применения
US20050153943A1 (en) *	2002-05-06	2005-07-14	Ashley Robert A.	Methods of simultaneously treating mucositis and fungal infection
US7959198B2 (en) *	2002-05-16	2011-06-14	Labor Saving Systems, Ltd.	Magnetic line retrieval system and method
IL152486A0 (en)	2002-10-25	2003-05-29	Meir Eini	Alcohol-free cosmetic and pharmaceutical foam carrier
US7704518B2 (en)	2003-08-04	2010-04-27	Foamix, Ltd.	Foamable vehicle and pharmaceutical compositions thereof
US8119109B2 (en)	2002-10-25	2012-02-21	Foamix Ltd.	Foamable compositions, kits and methods for hyperhidrosis
US10117812B2 (en)	2002-10-25	2018-11-06	Foamix Pharmaceuticals Ltd.	Foamable composition combining a polar solvent and a hydrophobic carrier
US9211259B2 (en)	2002-11-29	2015-12-15	Foamix Pharmaceuticals Ltd.	Antibiotic kit and composition and uses thereof
ES2532906T5 (es)	2002-10-25	2022-03-23	Foamix Pharmaceuticals Ltd	Espuma cosmética y farmacéutica
US9265725B2 (en)	2002-10-25	2016-02-23	Foamix Pharmaceuticals Ltd.	Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en)	2002-10-25	2010-04-20	Foamix, Ltd.	Penetrating pharmaceutical foam
US7820145B2 (en)	2003-08-04	2010-10-26	Foamix Ltd.	Oleaginous pharmaceutical and cosmetic foam
US9668972B2 (en) *	2002-10-25	2017-06-06	Foamix Pharmaceuticals Ltd.	Nonsteroidal immunomodulating kit and composition and uses thereof
US8486376B2 (en)	2002-10-25	2013-07-16	Foamix Ltd.	Moisturizing foam containing lanolin
US20080138296A1 (en)	2002-10-25	2008-06-12	Foamix Ltd.	Foam prepared from nanoemulsions and uses
US8119150B2 (en)	2002-10-25	2012-02-21	Foamix Ltd.	Non-flammable insecticide composition and uses thereof
US8900554B2 (en)	2002-10-25	2014-12-02	Foamix Pharmaceuticals Ltd.	Foamable composition and uses thereof
US6918987B2 (en) *	2003-02-07	2005-07-19	Lord Corporation	Surface preparation of rubber for coatings or bonding
ES2534827T3 (es)	2003-04-07	2015-04-29	Supernus Pharmaceuticals, Inc.	Formulaciones de tetraciclinas en dosis única diaria
US7575739B2 (en)	2003-04-28	2009-08-18	Foamix Ltd.	Foamable iodine composition
US8795693B2 (en)	2003-08-04	2014-08-05	Foamix Ltd.	Compositions with modulating agents
US8486374B2 (en)	2003-08-04	2013-07-16	Foamix Ltd.	Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20050074260A1 (en) *	2003-10-03	2005-04-07	Xerox Corporation	Printing apparatus and processes employing intermediate transfer with molten intermediate transfer materials
US7128412B2 (en)	2003-10-03	2006-10-31	Xerox Corporation	Printing processes employing intermediate transfer with molten intermediate transfer materials
KR20130122988A (ko) *	2005-03-14	2013-11-11	와이어쓰 엘엘씨	티게사이클린 조성물 및 이의 제조방법
MX2007015672A (es) *	2005-06-10	2008-02-20	Galderma Sa	Liberacion controlada de un farmaco a traves de la piel sobre la base de una composicion topica que comprende el farmaco, una silicona formadora de pelicula y al menos un solvente volatil.
US7919483B2 (en) *	2005-06-24	2011-04-05	Medicis Pharmaceutical Corporation	Method for the treatment of acne
US8252776B2 (en)	2007-04-02	2012-08-28	Medicis Pharmaceutical Corporation	Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en)	2005-06-24	2014-05-13	Medicis Pharmaceutical Corporation	Extended-release minocycline dosage forms
US9192615B2 (en)	2008-08-06	2015-11-24	Medicis Pharmaceutical Corporation	Method for the treatment of acne and certain dosage forms thereof
US20080242642A1 (en) *	2007-04-02	2008-10-02	Medicis Pharmaceutical Corporation	Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) *	2007-04-02	2009-06-09	Medicis Pharmaceutical Corporation	Minocycline oral dosage forms for the treatment of acne
US20080241235A1 (en) *	2007-04-02	2008-10-02	Medicis Pharmaceutical Corporation	Minocycline oral dosage forms for the treatment of acne
US7541347B2 (en) *	2007-04-02	2009-06-02	Medicis Pharmaceutical Coropration	Minocycline oral dosage forms for the treatment of acne
GEP20125432B (en)	2005-10-12	2012-03-26	Unimed Pharmaceuticals Llc	Improved testosterone gel and use thereof
US20080039433A1 (en) *	2006-06-15	2008-02-14	Smith Alexander D	Stabilized Tetracycline Compositions
TW200812645A (en) *	2006-06-15	2008-03-16	Serenex Inc	Tetracycline package formulations
US20080260655A1 (en)	2006-11-14	2008-10-23	Dov Tamarkin	Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
WO2008097850A1 (fr) *	2007-02-02	2008-08-14	Warner Chilcott Company, Inc.	Compositions de tétracycline pour une administration topique
US20080188446A1 (en) *	2007-02-02	2008-08-07	Warner Chilcott Company Inc.	Tetracycline compositions for topical administration
BRPI0808410A2 (pt) *	2007-02-28	2015-06-23	Aciex Therapeutics Inc	Métodos e composições para normalizar secreções da glândula meibomiana
US20080241197A1 (en) *	2007-04-02	2008-10-02	Medicis Pharmaceutical Corporation	Minocycline dosage forms for the treatment of acne
RU2345753C1 (ru) *	2007-06-18	2009-02-10	Александра Ивановна Африкантова	Способ лечения угревой болезни
HU227970B1 (en)	2007-07-10	2012-07-30	Egis Gyogyszergyar Nyrt	Pharmaceutical compositions containing silicones of high volatility
HUP0900072A2 (hu)	2009-02-06	2010-09-28	Egis Gyogyszergyar Nyilvanosan	Transzdermális gyógyszerkészítmények
US8636982B2 (en)	2007-08-07	2014-01-28	Foamix Ltd.	Wax foamable vehicle and pharmaceutical compositions thereof
WO2009064739A1 (fr) *	2007-11-16	2009-05-22	Dow Global Technologies Inc.	Ingrédients actifs liquides, hydrophobes, à faible viscosité et encapsulés
US9439857B2 (en)	2007-11-30	2016-09-13	Foamix Pharmaceuticals Ltd.	Foam containing benzoyl peroxide
US8518376B2 (en)	2007-12-07	2013-08-27	Foamix Ltd.	Oil-based foamable carriers and formulations
WO2009072007A2 (fr)	2007-12-07	2009-06-11	Foamix Ltd.	Porteurs, formulations, procédés pour formuler des agents actifs instables pour application externe et utilisations associées
EP2242476A2 (fr)	2008-01-14	2010-10-27	Foamix Ltd.	Compositions pharmaceutiques pouvant mousser de poloxamère avec des agents actifs et/ou des cellules thérapeutiques, et utilisations
FR2934495B1 (fr) *	2008-07-30	2010-12-17	Natura Cosmeticos Sa	Composition cosmetique conferant un effet mat et utilisation du beurre d'ucuhuba pour la preparation d'une telle composition cosmetique
WO2010125470A2 (fr)	2009-04-28	2010-11-04	Foamix Ltd.	Véhicule moussant et compositions pharmaceutiques comportant des solvants polaires aprotiques et leurs utilisations
PT104644B (pt)	2009-06-26	2012-11-06	Hovione Farmaciencia S A	Formulação tópica contendo uma tetraciclina e método de tratamento de infecções cutâneas usando a mesma
CA2769677A1 (fr)	2009-07-29	2011-02-03	Foamix Ltd.	Compositions hydro-alcooliques moussantes a base d'agents non tensioactifs non polymeres, mousses legeres, et leurs utilisations
WO2011013009A2 (fr)	2009-07-29	2011-02-03	Foamix Ltd.	Compositions hydro-alcooliques moussantes non tensioactives, mousses légères, et leurs utilisations
US20140121188A1 (en) *	2009-10-02	2014-05-01	Foamix Ltd.	Compositions for the improved treatment of acne and related disorders
WO2011064631A1 (fr)	2009-10-02	2011-06-03	Foamix Ltd.	Compositions moussantes dépourvues d'agent tensioactif et d'eau et mousses cassables et leurs utilisations
US9849142B2 (en)	2009-10-02	2017-12-26	Foamix Pharmaceuticals Ltd.	Methods for accelerated return of skin integrity and for the treatment of impetigo
US8174881B2 (en)	2009-11-24	2012-05-08	Micron Technology, Inc.	Techniques for reducing disturbance in a semiconductor device
US9561241B1 (en)	2011-06-28	2017-02-07	Medicis Pharmaceutical Corporation	Gastroretentive dosage forms for minocycline
US9119793B1 (en)	2011-06-28	2015-09-01	Medicis Pharmaceutical Corporation	Gastroretentive dosage forms for doxycycline
CN102631356B (zh) *	2012-04-11	2014-03-12	广州市东来生物科技有限公司	4-去二甲氨基四环素衍生物在抗幽门螺旋杆菌方面的用途
US10045935B2 (en)	2012-07-31	2018-08-14	Egis Pharmaceuticals Plc	Transdermal formulation containing COX inhibitors
US10045965B2 (en)	2012-07-31	2018-08-14	Egis Pharmaceuticals Plc	Transdermal formulation containing COX inhibitors
US11154535B2 (en)	2012-07-31	2021-10-26	Egis Pharmaceuticals Plc	Transdermal formulation containing COX inhibitors
PT106679B (pt) *	2012-11-27	2015-03-25	Hovione Farmaciencia Sa	Formulações tópicas de tetraciclinas, sua preparação e usos
US10842802B2 (en)	2013-03-15	2020-11-24	Medicis Pharmaceutical Corporation	Controlled release pharmaceutical dosage forms
US20160287614A1 (en) *	2013-11-20	2016-10-06	Lupin Limited	Stable Pharmaceutical Formulation(s) of Tetracycline Antibiotic
AU2016224863A1 (en)	2015-02-25	2017-10-12	Sun Pharma Advanced Research Company Ltd	Nanoparticulate composition
KR20170134514A (ko)	2015-03-23	2017-12-06	바이오팜엑스 인코포레이티드	피부과 사용을 위한 약학 테트라사이클린 조성물
EP3346998B1 (fr) *	2015-08-17	2025-04-16	Sidmak Laboratories (India) PVT. Ltd.	Système d'administration de film par voie topique
US10398641B2 (en)	2016-09-08	2019-09-03	Foamix Pharmaceuticals Ltd.	Compositions and methods for treating rosacea and acne
CA3078783A1 (fr) *	2017-10-24	2019-05-02	Glenmark Pharmaceuticals Limited	Composition pharmaceutique topique d'adapalene et de minocycline
TWI841543B (zh)	2017-11-28	2024-05-11	德商Ｃ樂克塔股份有限公司	生產海藻糖之方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4058491A (en) *	1975-02-11	1977-11-15	Plastomedical Sciences, Inc.	Cationic hydrogels based on heterocyclic N-vinyl monomers
US4140656A (en) *	1977-10-07	1979-02-20	Armour-Dial, Inc.	Anhydrous clear gel facial cleanser
US4200561A (en) *	1978-07-17	1980-04-29	Allied Chemical Corporation	Stable, compatible thixotropic gel with copolymer gelling agent
US4376118A (en) *	1980-10-06	1983-03-08	Miles Laboratories, Inc.	Stable nonaqueous solution of tetracycline salt
US4411893A (en) *	1981-08-14	1983-10-25	Minnesota Mining And Manufacturing Company	Topical medicament preparations
US4701320A (en) *	1984-11-29	1987-10-20	Lederle (Japan), Ltd.	Composition stably containing minocycline for treating periodontal diseases

1989
- 1989-06-27 US US07/371,948 patent/US5122519A/en not_active Expired - Fee Related
1990
- 1990-05-21 EP EP90109631A patent/EP0410099A1/fr not_active Withdrawn
- 1990-05-24 IL IL94490A patent/IL94490A0/xx unknown
- 1990-06-15 CN CN90103011A patent/CN1048322A/zh active Pending
- 1990-06-22 JP JP2162978A patent/JPH0348615A/ja active Pending
- 1990-06-25 CA CA002019724A patent/CA2019724A1/fr not_active Abandoned
- 1990-06-25 PT PT94485A patent/PT94485A/pt not_active Application Discontinuation
- 1990-06-25 CS CS903144A patent/CS314490A2/cs unknown
- 1990-06-26 AU AU57899/90A patent/AU5789990A/en not_active Abandoned
- 1990-06-26 KR KR1019900009480A patent/KR910000162A/ko not_active Withdrawn
- 1990-06-26 ZA ZA904971A patent/ZA904971B/xx unknown
- 1990-06-26 NO NO90902828A patent/NO902828L/no unknown
- 1990-06-26 IE IE230790A patent/IE902307A1/en unknown
- 1990-06-26 HU HU903993A patent/HU204435B/hu not_active IP Right Cessation
- 1990-06-26 FI FI903216A patent/FI903216A7/fi not_active IP Right Cessation
- 1990-06-27 PL PL28581390A patent/PL285813A1/xx unknown

Also Published As

Publication number	Publication date
AU5789990A (en)	1991-01-03
NO902828L (no)	1990-12-28
NO902828D0 (no)	1990-06-26
PL285813A1 (en)	1991-02-11
HUT54052A (en)	1991-01-28
FI903216A7 (fi)	1990-12-28
US5122519A (en)	1992-06-16
HU204435B (en)	1992-01-28
KR910000162A (ko)	1991-01-29
CA2019724A1 (fr)	1990-12-27
HU903993D0 (en)	1990-11-28
CN1048322A (zh)	1991-01-09
IE902307L (en)	1990-12-27
IE902307A1 (en)	1991-01-16
JPH0348615A (ja)	1991-03-01
FI903216A0 (fi)	1990-06-26
IL94490A0 (en)	1991-03-10
PT94485A (pt)	1991-02-08
EP0410099A1 (fr)	1991-01-30
ZA904971B (en)	1991-04-24

Publication	Publication Date	Title
CS314490A2 (en)	1991-11-12	Stable, cosmetically acceptable topic gel-like preparation
FI104407B (fi)	2000-01-31	Menetelmä ihonhoitokoostumusten valmistamiseksi
RU2134101C1 (ru)	1999-08-10	Стабильные местнодействующие ретиноидные композиции
US3535422A (en)	1970-10-20	Stable benzoyl peroxide composition
JP3014780B2 (ja)	2000-02-28	スキンケア組成物
US5690919A (en)	1997-11-25	Deodorizing cosmetic compositions
EP2046277B1 (fr)	2011-01-19	Préparations cosmétiques ou dermatologiques contenant de la n-acétylcystéine
JPS59134726A (ja)	1984-08-02	低誘電溶媒を含有する貯蔵安定な局所薬剤組成物
JPWO2001085156A1 (ja)	2003-07-29	補酵素ｑを有効成分とする皮膚用組成物
US4923862A (en)	1990-05-08	Topical preparation containing ofloxacin
US4261982A (en)	1981-04-14	Therapeutic composition
US4495203A (en)	1985-01-22	Anhydrous composition, stable to oxidation, based on anthralin or one of its derivatives, in a carrier consisting of a fatty acid alkyl ester and a thickener, and its use in the treatment of skin diseases
JP3582016B2 (ja)	2004-10-27	皮膚外用剤
JPH0340009B2 (fr)	1991-06-17
US4621075A (en)	1986-11-04	Gel-form topical antibiotic compositions
GB1587428A (en)	1981-04-01	Anti-acne compositions containing erythromycins
CA1057662A (fr)	1979-07-03	Compose a usage local contre l'acne
CN1768724B (zh)	2010-07-21	水包油型皮肤外用组合物
KR102018128B1 (ko)	2019-09-04	여드름 개선을 위한 pH 감응성 화장료 조성물 및 이의 제조방법
JPS63188628A (ja)	1988-08-04	皮膚外用剤
JPH03120230A (ja)	1991-05-22	薬効成分の経皮吸収促進剤及び経皮吸収型製剤
JPH03157311A (ja)	1991-07-05	にきび用化粧料
IE47494B1 (en)	1984-04-04	An erythormycin compound,a process for preparing the compound and compositions containing the compound useful in the treatment of acne
JPH0399010A (ja)	1991-04-24	医薬組成物
EP0640581A1 (fr)	1995-03-01	Matière nourricière endermique et composition cosmétique qui la contient